ImmunityBio reports $75 million in year-to-date sales and narrows net loss for Q3 2025
ImmunityBio Inc. reported a significant increase in product revenue, reaching $31.8 million in Q3 2025, up 434% from $6.0 million in Q3 2024. Year-to-date sales totaled $74.7 million, a 467% increase in unit volume compared to the same period last year. The net loss for Q3 2025 was $67.3 million, improved from $85.7 million in Q3 2024. For the first nine months of 2025, the net loss was $289.5 million, down from $354.4 million in 2024. As of September 30, 2025, the company had $257.8 million in cash and equivalents.
ImmunityBio Inc. reported product revenue of $31.8 million for the third quarter of 2025, a 434% increase from $6.0 million in the same period of 2024. Year-to-date sales reached $74.7 million, reflecting a 467% increase in unit volume compared to the last three quarters of 2024. The company recorded a net loss attributable to common stockholders of $67.3 million for the third quarter of 2025, compared to $85.7 million in the third quarter of 2024. For the first nine months of 2025, the net loss was $289.5 million, down from $354.4 million for the same period in 2024. As of September 30, 2025, ImmunityBio had $257.8 million in cash, cash equivalents, and marketable securities. The increase in revenue was primarily driven by continued commercial uptake of ANKTIVA in combination with BCG for BCG-unresponsive NMIBC with CIS, with or without papillary tumors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104215288) on November 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
